The science mystery: how researchers cracked the code of the body’s most elegant healing signal

The question that couldn’t be ignored

Science is uncomfortable with «it works, but we don’t know why.» That discomfort is productive: it drives the kind of relentless inquiry that turns empirical observation into genuine understanding. By the late 1990s, the evidence that PDRN accelerated healing was strong enough to be clinically credible, but the mechanism – the cellular language by which these DNA fragments were communicating with human tissue – remained elusive.

The central puzzle was deceptively simple. DNA’s primary job in any cell is to serve as a blueprint: a master set of instructions for building proteins. But PDRN fragments were too small to carry complete genetic instructions. These short chains of deoxyribonucleotides, typically between 50 and 2,000 base pairs long, couldn’t be telling cells what proteins to make. So what exactly were they doing? How were fragments of DNA triggering such profound and consistent healing responses in human tissue?

The hypothesis that made the most intuitive sense, that PDRN was simply donating raw nucleotide material for cells to rebuild their own damaged DNA, was partially correct, but it turned out to be only half the story. The other half would prove to be far more surprising, and far more clinically important.

The landmark discovery: a receptor, a lock, and a key

In 1999, a team of researchers published a study that would reshape the understanding of PDRN entirely. Scientists exposed primary cultures of human skin fibroblasts, the cells deep in the dermis responsible for making collagen and maintaining skin’s structural integrity, to PDRN. The results confirmed what clinicians had been observing: fibroblast growth rate increased. Cells multiplied. Healing activity accelerated.

But the researchers added a critical experimental twist. They introduced a chemical called DMPX (3,7-dimethyl-1-propargylxanthine) – a selective blocker of a specific cellular receptor called the adenosine A2A receptor. When DMPX was present, PDRN’s proliferative effects disappeared almost entirely. The growth stimulation vanished. The healing signal went silent.

Then the researchers tested the opposite. They used a chemical that mimics A2A receptor activation (an A2 receptor agonist called DPMA) without any PDRN at all. The fibroblasts responded almost identically to how they responded to PDRN itself. And when they used chemicals that blocked other adenosine receptor subtypes (A1 receptors), PDRN’s effects were completely unaffected, suggesting the A2A subtype was the specific and critical target.

The conclusion was elegant and definitive: PDRN was functioning as a pro-drug, a biological precursor that the body converts into active compounds which then bind specifically to the adenosine A2A receptor. The receptor was the lock. Adenosine, released when PDRN was enzymatically broken down by the body, was the key. And the healing effects were the door swinging open.

Inside the A2A receptor: A G-protein cascade worth understanding

To appreciate why this discovery mattered so much, it helps to understand what the adenosine A2A receptor actually is and what it does, because this is where the science becomes truly remarkable.

The A2A receptor belongs to a class called G protein-coupled receptors (GPCRs), the largest family of cell-surface signalling proteins in the human genome. When a molecule like adenosine binds to the A2A receptor from outside the cell, it triggers a conformational change a physical shape-shift in the receptor protein, that activates a G protein (specifically Gs) on the inside of the cell membrane. This activated G protein then stimulates an enzyme called adenylyl cyclase, which converts ATP into a small but enormously influential messenger molecule: cyclic AMP (cAMP).

From there, cAMP acts like an orchestral conductor inside the cell. It activates Protein Kinase A (PKA), which in turn phosphorylates (chemically activates) a transcription factor called CREB (cAMP Response Element Binding Protein). When CREB is phosphorylated, it moves to the nucleus and activates specific gene promoters, essentially switching on a portfolio of regenerative, anti-inflammatory, and pro-angiogenic genes.

What this means in practical terms is profound: a single binding event at the cell surface, PDRN-derived adenosine attaching to an A2A receptor, triggers a cascade that reaches all the way into the cell’s nucleus and changes what genes are being expressed. The cell receives what is essentially a command: activate repair mode.

Importantly, the A2A receptor pathway also suppresses NF-κB – the so-called «master switch» of inflammation. When cAMP and PKA are elevated through A2A activation, they inhibit NF-κB from translocating into the nucleus. Since NF-κB is the transcription factor responsible for producing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8, blocking it has the simultaneous effect of reducing tissue-damaging inflammation while promoting regeneration. This dual property, anti-inflammatory and pro-regenerative, is what makes PDRN so clinically versatile.

The second mechanism: feeding the cellular recycling plant

The A2A receptor pathway was the headline discovery, but it wasn’t the complete story. A second mechanism, working in parallel, added an extraordinary dimension to PDRN’s biology: the nucleotide salvage pathway.

When extracellular enzymes (nucleases) break PDRN down in tissue, they don’t just produce adenosine. They produce the full complement of deoxyribonucleosides: deoxyadenosine, deoxyguanosine, deoxycytidine, and thymidine – the four building blocks of DNA itself. These individual nucleosides are absorbed by surrounding cells and fed directly into the salvage pathway, where they are phosphorylated into deoxyribonucleotide triphosphates (dNTPs) – the active currency that DNA polymerases use during replication.

The significance of this is easy to underestimate. Normally, cells synthesise fresh nucleotides through a complex, energetically expensive process called de novo synthesis – essentially building nucleotides from scratch. This process requires significant metabolic energy. In tissue that is wounded, chronically stressed, hypoxic, or aged, the cellular energy budget is compromised. De novo synthesis slows. Cells struggle to replicate. Healing stalls.

The salvage pathway offers an energetically cheap alternative: recycle existing nucleosides instead of building new ones from scratch. PDRN essentially floods this salvage pathway with substrate. By providing all four deoxyribonucleoside types simultaneously, and in the natural ratios present in any DNA, it replenishes nucleotide pools in a balanced way, without skewing the ratio of one nucleotide type over another (which would otherwise increase replication errors and genomic instability).

This creates a uniquely powerful dual action that no simple receptor agonist can replicate: PDRN simultaneously signals cells to regenerate (through the A2A receptor cascade) and supplies the molecular fuel those cells need to actually complete DNA replication and divide. It delivers both the instruction and the raw materials.

Why wounds fail and how PDRN fixes It

The most compelling early validation of PDRN’s dual mechanism came from diabetic wound models. Diabetic wounds are one of medicine’s most stubborn problems. Chronic hyperglycaemia damages blood vessel walls, impairing circulation. Tissue becomes hypoxic, starved of oxygen. Inflammatory cytokines become chronically elevated, creating a destructive loop that prevents healing from progressing past its earliest inflammatory phase.

Specifically, diabetic wounds exhibit critically depressed levels of Vascular Endothelial Growth Factor (VEGF), the master regulator of new blood vessel formation. Without adequate VEGF, capillaries cannot form. Without new capillaries, oxygen cannot reach the wound. Without oxygen, cells cannot regenerate. The wound persists, enlarges, and frequently leads to infection, gangrene, and amputation.

In 2008, Galeano and colleagues published a landmark study in Wound Repair and Regeneration testing PDRN in a genetically diabetic mouse model. Their findings were striking: PDRN-treated animals showed a statistically significant increase in VEGF mRNA and protein in wound tissue by day six compared to vehicle-treated controls. This VEGF increase was accompanied by elevated expression of CD31 (a marker of new vessel formation), angiopoietin-1 (which stabilises newly formed vessels), and transglutaminase-II (involved in tissue remodelling). Wound-breaking strength at day twelve was substantially improved.

Critically, all of these effects were abolished when DMPX was co-administered. This was the confirmatory proof: VEGF upregulation was happening through the A2A receptor pathway, not through some non-specific effect of excess nucleotides.

These preclinical findings translated directly into human benefit. A landmark 2014 randomised, double-blind, placebo-controlled clinical trial enrolled 216 diabetic patients with chronic foot ulcers. After eight weeks, complete healing was achieved in only 18.9% of placebo patients, compared to 37.3% in the PDRN group, nearly double. The median time to complete wound healing was 30 days with PDRN versus 49 days with placebo. For patients facing the very real risk of amputation, these numbers were transformative.

The ERK pathway: smarter than a simple switch

As research continued into the 2000s and 2010s, scientists discovered that PDRN’s cellular effects were even more sophisticated than the original A2A/cAMP model suggested. A 2023 study in Molecular Medicine Reports investigated how PDRN affects the ERK (extracellular signal-regulated kinase) pathway in two different cell types: fibroblasts and keratinocytes (the outer skin cells).

The results were fascinatingly context-dependent. In fibroblasts, PDRN increased ERK phosphorylation, which drove upregulation of collagen type I and type III synthesis and simultaneously suppressed matrix metalloproteinases (MMPs), the enzymes that degrade collagen in aged or damaged skin. When researchers blocked ERK with the inhibitor PD98059, PDRN’s collagen-boosting effects disappeared.

In keratinocytes, PDRN did the opposite, it inhibited ERK phosphorylation, which suppressed the production of pro-inflammatory cytokines. The same molecule, acting on two adjacent cell types in the skin, was doing fundamentally different things, but both were exactly what the skin needed: more structural collagen from fibroblasts, and less inflammatory noise from keratinocytes.

This context-sensitivity is extraordinary. PDRN is not a blunt instrument forcing a single outcome on all cells. It is a nuanced biological agent that calibrates its effects to serve the tissue’s specific regenerative needs depending on what type of cell it encounters.

The Ischemia insight: flipping the switch from distress to recovery

Further mechanistic discovery came from research on ischemic skin flaps, a surgical situation where tissue temporarily loses blood supply and risks necrosis. Scientists studying PDRN in these models observed that treatment dramatically restored blood flow and promoted complete re-epithelialization, measurable as early as day five.

Intriguingly, PDRN both increased VEGF expression (driving vessel formation) and reduced expression of HIF-1α – the «hypoxia-inducible factor» that accumulates when tissue is oxygen-deprived. HIF-1α serves as a cellular distress signal; chronically elevated HIF-1α can paradoxically impair healing by perpetuating a hypoxic signalling environment even after oxygen supply is restored. PDRN’s ability to reduce HIF-1α while simultaneously promoting VEGF and vessel formation means it was effectively switching ischemic tissue from a distress state to a recovery state – closing the loop on the hypoxic injury cycle.

Why this science matters for your skin

The gap between hospital wound care and everyday skincare might seem vast, but mechanistically it is a small step. The cellular events that drive diabetic wound healing and the cellular events that drive aesthetic skin regeneration are mediated by the same pathways: fibroblast proliferation, collagen synthesis, MMP suppression, VEGF-driven microvascular support, and NF-κB-mediated inflammation control.

Skin aging is, in cellular terms, a slow convergence of the conditions that create chronic wounds: chronically elevated inflammatory cytokines (inflammaging), depleted collagen from chronically elevated MMPs, reduced fibroblast activity, impaired microcirculation, and DNA damage from UV radiation that outpaces the salvage pathway’s ability to repair it.

When Korean dermatologists began using PDRN as an aesthetic injectable in the 2010s, they were not guessing or following a beauty trend. They were applying two decades of mechanistic science – knowing exactly which cellular pathways they were activating, and why those pathways would produce the outcomes they observed: thicker dermis, smoother texture, improved elasticity, reduced fine lines.

…The science wasn’t borrowed from beauty. The beauty was born from the science…

What makes PDRN unique among A2A agonists

One final point worth appreciating: PDRN is not the only adenosine A2A receptor agonist in medicine. Regadenoson, approved by the FDA as a cardiac stress agent, is another. But PDRN’s dual mechanism, signalling and substrate, means it occupies a category of its own. Pure receptor agonists can activate the healing signal, but they cannot supply the nucleotide building materials that allow cells to actually complete DNA replication. Conversely, simple nucleotide supplementation cannot supply the receptor-level activation signal.

PDRN does both. And according to the 2017 comprehensive review by Squadrito and colleagues in Frontiers in Pharmacology, one of the most cited papers in this field, this dual action is directly linked to PDRN’s specific DNA origin, molecular weight range (50–1,500 kDa), and manufacturing process. Not all PDRN products are equivalent: the biological activity depends on having the right chain lengths, the right purity, and the right production method. This is why the manufacturing science matters as much as the biology.

The foundation is set

By the early 2010s, the scientific community had a clear, multi-layered picture of how PDRN worked at the molecular level. It was a pro-drug that generated A2A receptor agonists, triggering a cAMP-PKA-CREB cascade that switched on regenerative gene expression and suppressed inflammatory NF-κB signalling. It simultaneously fed the nucleotide salvage pathway, providing metabolically economical building blocks for DNA synthesis in energy-compromised tissue. It modulated ERK signalling in a cell-type-specific manner. It upregulated VEGF, promoted angiogenesis, and countered ischemia-related HIF-1α accumulation.

This was not a molecule of mysteries anymore. It was a molecule of mechanisms, well-characterised, clinically validated, and ready to transform aesthetic medicine.

In Part 3, we’ll explore how this mechanistic understanding led researchers to test PDRN across an astonishing range sources for range of medical conditions, from burns and orthopedic injuries to ophthalmology and neurology, proving that when you activate the body’s fundamental repair language, the applications are limited only by imagination.

Key scientific references

1. Thellung S, et al. (1999). Involvement of A2 purinergic receptor subtypes in the trophic activity of PDRN on human skin fibroblasts. Life Sciences. PMID: 10328526.
2. Squadrito F, et al. (2017). Pharmacological Activity and Clinical Use of PDRN. Frontiers in Pharmacology, 8:224. PMC5405115.
3. Galeano M, et al. (2008). Polydeoxyribonucleotide stimulates angiogenesis and wound healing in a diabetic mouse model. Wound Repair and Regeneration, 16(2):208–215. PMID: 18318806.
4. Altavilla D, et al. (2014). The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers. Journal of Clinical Endocrinology & Metabolism, 99(5):E746–E753. PMID: 24483158.
5. Kim JH, et al. (2023). Polydeoxyribonucleotide exerts opposing effects on ERK activity in human skin keratinocytes and fibroblasts. Molecular Medicine Reports, 28(3):166. PMID: 37350391.
6. Ko MH, et al. (2024). Polydeoxyribonucleotide ameliorates IL-1β-induced impairment of chondrogenic differentiation. Scientific Reports, 14:25668. PMC11576977.
7. Galeano M, et al. (2012). Polydeoxyribonucleotide restores blood flow in an experimental model of ischemic skin flaps. Journal of Vascular Surgery, 55(2):479–488. PMID: 22051873.
8. Park KY, et al. (2023). Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology. Pharmaceuticals, 16(8):1092. PMC12388916.
9. Squadrito F, et al. (2020). PDRN ameliorates imiquimod-induced psoriasis through NF-κB pathway inhibition. Cell Transplantation, 29:963689718804130. PMC7072802.
10. Park JS, et al. (2021). Adenosine A2A receptor agonist PDRN ameliorates memory impairment in cerebral ischemia. International Journal of Molecular Sciences, 22(6):2900. PMC7971468.
11. Fredholm BB, et al. (2008). The A2A adenosine receptor: a GPCR with unique features? British Journal of Pharmacology, 153(S1):S310–S321. PMC2268059.
12. Kim HY, et al. (2025). Versatile and Marvelous Potentials of PDRN for Tissue Engineering and Regeneration. Biomaterials Research, 29:0183. PMC11994882.